Bio-Gene Technology (ASX:BGT) EBITDA Margin % : -8,621.05% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Bio-Gene Technology EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bio-Gene Technology's EBITDA for the six months ended in Dec. 2023 was A$-1.64 Mil. Bio-Gene Technology's Revenue for the six months ended in Dec. 2023 was A$0.02 Mil. Therefore, Bio-Gene Technology's EBITDA margin for the quarter that ended in Dec. 2023 was -8,621.05%.

Bio-Gene Technology EBITDA Margin % Historical Data

The historical data trend for Bio-Gene Technology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Gene Technology EBITDA Margin % Chart

Bio-Gene Technology Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBITDA Margin %

Get a 7-Day Free Trial

-421.61

-231.50

-420.77

-332.95

-527.23

Bio-Gene Technology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial								-423.21	-273.63	-	-	-8,621.05

Competitive Comparison of Bio-Gene Technology's EBITDA Margin %

For the Biotechnology subindustry, Bio-Gene Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gene Technology's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's EBITDA Margin % falls into.

Bio-Gene Technology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bio-Gene Technology's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-3.137	/	0.595
	=	-527.23 %

Bio-Gene Technology's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.638	/	0.019
	=	-8,621.05 %

Bio-Gene Technology (ASX:BGT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bio-Gene Technology EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Bio-Gene Technology's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Gene Technology (ASX:BGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Gene Technology Ltd (ASX:BGT) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000

Website

https://www.bio-gene.com.au

Bio-Gene Technology Ltd is an Australian biotechnology company engaged in the development and commercialization of insecticide products. It develops a patent-protected product platform based on a naturally occurring class of chemicals known as beta-triketones. Its product includes Qcide and Flavocid. Its target applications include agriculture, public health, and consumer and animal health. The firm operates in one business segment namely the conduct of research and development activities in the discovery of novel insecticides.

Bio-Gene Technology (ASX:BGT) Headlines

From GuruFocus

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

By Business Wire Business Wire • 12-20-2021